Skip to content
Tuesday, August 16, 2022
Latest:
  • Researchers identify an Achilles’ heel in neuroblastoma
  • Welcome new residents and fellows!
  • Forced to flee: Barriers to care in local refugee populations
  • Throwback Thursday: The first Image of the Month
  • When should you start your child in swimming lessons?

Baylor College of Medicine Blog Network

Baylor College of Medicine Blog Network

  • Home
  • Momentum
    • About Momentum
    • Resources
    • Contributors
      • Dana Benson
      • Molly Chiu
      • Julie Garcia
      • Graciela Gutierrez
      • Anna Kiappes
      • Dipali Pathak
      • Andy Phifer
      • Homa Shalchi
      • Melissa Tucker
    • Contact Us
  • From The Labs
    • About From the Labs
    • Follow From The Labs on Twitter
  • Policywise
    • About PolicyWise
    • Follow @BCMEthics on Twitter
  • The Stitch
    • About The Stitch
  • Progress Notes
    • About Progress Notes
    • Progress Notes Editors
    • Connect With Us
  • bcm.edu

CDK4/6 inhibitor therapy

From The Labs 

Interferon linked to ER+/HER- metastatic breast cancer resistance to therapy

March 12, 2021March 12, 2021CDK4/6 inhibitor therapy, endocrine therapy, ER+/HER2- breast cancer, Interferon, Metastatic breast cancer, Research, resistance to cancr treatment

Both preclinical models and tumor samples from patients with ER+/HER2- breast cancer link high IFN signaling to resistance to treatment.

Read more

From the Labs Video of the Month

From The Labs Image of the Month From the Labs: A beating developing mouse heart.

Healthy Habits: A DOC-umentary Series

https://www.youtube.com/watch?v=SlNiMWHUhbc

Archives

Search

©1998 - 2020 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951